Literature DB >> 17568823

Management of chronic hepatitis B: consensus guidelines.

Morris Sherman1, Stephen Shafran, Kelly Burak, Karen Doucette, Winnie Wong, Nigel Girgrah, Eric Yoshida, Eberhard Renner, Philip Wong, Marc Deschênes.   

Abstract

The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada. Several new agents have become available since the last such document was published in 2004, and new information has become available to help assess risk of adverse outcomes and who should be treated. In addition, the participants at the meeting identified a number of structural barriers that exist uniquely in Canada and that prevent physicians from properly managing their patients. The conference discussed the selection of patients for treatment and the drugs that can be used to treat these patients, as well as the treatment of hepatitis B in special populations. The present document should be read in conjunction with the companion document on the management of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568823      PMCID: PMC2794455     

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  143 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis.

Authors:  J H Wang; S N Lu; C M Lee; J F Lee; Y P Chou
Journal:  Scand J Gastroenterol       Date:  2002-03       Impact factor: 2.423

3.  Clinical trial of lamivudine in children with chronic hepatitis B.

Authors:  Maureen M Jonas; Deirdre A Kelley; Jacek Mizerski; Isabel B Badia; Jorge A Areias; Kathleen B Schwarz; Nancy R Little; Martin J Greensmith; Stephen D Gardner; M Steve Bell; Etienne M Sokal
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

4.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Authors:  Y Benhamou; M Bochet; V Thibault; V Calvez; M H Fievet; P Vig; C S Gibbs; C Brosgart; J Fry; H Namini; C Katlama; T Poynard
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

5.  Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.

Authors:  B J McMahon; P Holck; L Bulkow; M Snowball
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

6.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

Authors:  F Trevisani; P E D'Intino; A M Morselli-Labate; G Mazzella; E Accogli; P Caraceni; M Domenicali; S De Notariis; E Roda; M Bernardi
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

7.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.

Authors:  B C Song; D J Suh; H C Lee; Y H Chung; Y S Lee
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

8.  Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.

Authors:  C A Sponseller; B R Bacon; A M Di Bisceglie
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

9.  An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques.

Authors:  J Saldanha; W Gerlich; N Lelie; P Dawson; K Heermann; A Heath
Journal:  Vox Sang       Date:  2001-01       Impact factor: 2.144

10.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

Authors:  M F Yuen; E Sablon; C K Hui; H J Yuan; H Decraemer; C L Lai
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

View more
  36 in total

1.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis.

Authors:  Tahir Shaikh; Curtis Cooper
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

3.  Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.

Authors:  Morris Sherman; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

4.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

5.  Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey.

Authors:  Justina Joyce Sam; E Jenny Heathcote; David Kh Wong; Douglas L Wooster; Hemant Shah
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

Review 6.  Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.

Authors:  Daniel Benten; Katharina Staufer; Martina Sterneck
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

7.  Information technology and infectious diseases: Promise and pitfalls.

Authors:  A Mark Joffe
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-11       Impact factor: 2.471

8.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 9.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

10.  Canadian trends in liver cancer: a brief clinical and epidemiologic overview.

Authors:  P De; D Dryer; M C Otterstatter; R Semenciw
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.